Skip to main content Accessibility help
  • Print publication year: 2009
  • Online publication date: May 2010

16 - Acute therapies and interventions

from Section IV - Therapeutic strategies and neurorehabilitation



Over recent decades the early management of acute stroke has changed dramatically and the early post-stroke period has been the focus of much research. With advances in pharmacotherapeutics, and on the basis of many randomized controlled trials, the potential interventions now available within the first 24–48 hours following acute stroke are numerous.

This chapter will present the evidence and best practice guidance for interventions during the first 24–48 hours following stroke, based upon the European Stroke Organisation Guidelines 2008 and the European Stroke Initiative recommendations for the management of intracranial hemorrhage [1,2]. For the purposes of this chapter, the interventions discussed will generally be limited to the initial 48 hours following ictus. Access to some of these therapies may not be universal and may be dictated by local availability at individual stroke units. As with other aspects of stroke care, however, close cooperation and inter-disciplinary communication are essential.


In respect of acute interventions, one of the most significant advances during the last two decades has been the introduction of intravenous thrombolysis as a standard therapy for a well-selected population of patients with acute ischemic stroke. At present, the only thrombolytic agent licensed in Europe for the treatment of ischemic stroke is recombinant-tissue plasminogen activator (rtPA), alteplase.

,The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee. Guidelines for the management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25:457–507.
,The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Recommendations for the Management of Intracranial Haemorrhage – Part 1: Spontaneous Intracerebral Haemorrhage. Cerebrovasc Dis 2006; 22:294–316.
Hacke, W, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274(13): 1017–25.
,The National Institute of Neurological Disorders and Stroke rt-PA stroke study group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med 1995; 333:1581–8.
Hacke, W, et al. Randomised double-blind placebo controlled trial of thrombolytic therapy with intravenous Alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352:1245–51.
Clark, WM, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study: a Randomized Controlled Trial. JAMA 1999; 282(21):2019–26.
Hacke, W, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Lancet 2004; 363:768–74.
Lansberg, MG, et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007; 38(8):2275–8.
Sylaja, PN, et al. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 2006; 77(7):826–9.
Molina, CA, et al. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke 2006; 37(2):425–9.
Wahlgren, N, et al. Thrombolysis with Alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369:275–82.
Smith, WS, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI Trial. Stroke 2005; 36(7):1432–8.
,Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308(6921):81–106.
,International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997; 349:1569–81.
,CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997; 349:1641–9.
Wardlaw, JM, et al. What is the best imaging strategy for acute stroke?Health Technol Assess 2004; 8:1–180.
,Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329):71–86.
,The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367:1665–73.
Sacco, RL, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359(12):1238–51.
Markus, HS, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) Trial. Circulation 2005; 111(17):2233–40.
Diener, H-C, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:331–37.
Gubitz, G, Sandercock, P, Counsell, C. Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2004; CD000024.
Paciaroni, M, et al. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007; 38(2):423–30.
Ashfaq Shuaib, , et al. NXY-059 for the treatment of acute ischaemic stroke. N Engl J Med 2007; 357:562–71.
Friday, G, Alter, M, Lai, S-M. Control of hypertension and risk of stroke recurrence. Stroke 2002; 33(11):2652–7.
Robinson, TG, Potter, JF. Blood pressure in acute stroke. Age Ageing 2004; 33:6–12.
Leonardi-Bee, J, et al. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33:1315–20.
Brott, T, et al. Hypertension and its treatment in the NINDS rt-PA stroke trial. Stroke 1998; 29:1504–9.
Bath, P, et al. International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. J Hypertens 2003; 21:665–72.
Castillo, J, et al. Blood pressure decrease during the acute phase of ischaemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004; 35:520–7.
Oliveira-Filho, J, et al. Detrimental effect of blood pressure reduction in the first 24 hours of acute stroke onset. Neurology 2003; 61:1047–51.
Willmot, M, Leonardi-Bee, J, Bath, PM. High blood pressure in acute stroke and subsequent outcome. A systemic review. Hypertension 2004; 43:18–24.
Eames, P, et al. Dynamic cerebral autoregulation and beat to beat blood pressure control are impaired in acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2002; 72:467–72.
Powers, W. Acute hypertension after stroke: the scientific basis for treatment decisions. Neurology 1993; 43:461–7.
Mattle, HP, et al. Blood pressure and vessel recanalization in the first hours after ischemic stroke. Stroke 2005; 36:264–9.
Tsivgoulis, G, et al. Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke. Stroke 2007; 38:961–6.
,Continue or Stop Antihypertensives Collaboration Study. 2005. [cited 18 June 2005].
,Blood Pressure in Acute Stroke Collaboration (BASC). Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database of Systematic Reviews, 2001; Issue 3. CD000039. DOI 10.1002/114651858.CD000039.
O'Connell, J, Gray, C. Treatment of post-stroke hypertension. A practical guide. Drugs Aging 1996; 8(6):408–15.
Adams, HP, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38(5):1655–711.
Capes, SE, et al. Stress hyperglycaemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001; 32:2426–32.
Scott, J, et al. Glucose and insulin therapy in acute stroke; why delay further?Q J Med 1998; 91:511–15.
Weir, CJ, et al. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study. BMJ 1997; 314:1303–6.
Malmberg, K, et al. Randomised trial of insulin glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction. The DIGAMI Study. J Am Coll Cardiol 1995; 26:57–65.
Berghe, G, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359–67.
Gray, CS, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 2007; 6:397–406.
Vahedi, K, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 2007; 6:215–22.
Anderson, CS, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 2008; 7(5):391–9.
Quresh, AI. Antihypertensive treatment of acute cerebral haemorrhage (ATACH). In International Stroke Conference, New Orleans, LA, USA. 2008.
Albers, GW, et al. Antithrombotic and antithrombolytic therapy for ischaemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:483S–512S.
Mendelow, AD, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005; 365(9457):387–97.
Mayer, SA, et al. Recombinant activated Factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352(8):777–85.
Mayer, SA, et al. Efficacy and safety of recombinant activated Factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358(20):2127–37.
Wahlgren, N, et al. for the SITS investigators. Thrombolysis with alteplase 3 to 4.5 h after acute ischaemic stroke in the Safe Implementation of Treatments in Stroke Register (SITS-ISTR): an observational study. Lancet 2008; 372(9646):1303–9.
Hacke, W, et al. for the European Cooperative Acute Stroke Study (ECASS) investigators. Alteplase compared with placebo within 3 to 4.5 hours for acute ischemic stroke. N Engl J Med 2008; 359:1317–29.